Alternatives to Praziquantel for the Prevention and Control of Schistosomiasis

被引：39

作者：

Spangenberg, Thomas ^{[1
]}

机构：

[1] Ares Trading SA, Global Hlth Inst Merck, CH-1262 Eysins, Switzerland

来源：

ACS INFECTIOUS DISEASES | 2021年 / 7卷 / 05期

关键词：

IN-VITRO;

D O I：

10.1021/acsinfecdis.0c00542

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Schistosomiasis, a neglected tropical disease provoked by infection with parasitic blood flukes of the genus Schistosoma, affects almost 240 million people worldwide, and more than 700 million people live in endemic areas. However, 40 years after the approval of praziquantel as an anthelmintic drug, the pipeline is nearly empty, and no other therapeutic alternative has reached the market. In its roadmap to "eliminate Schistosomiasis as a public health problem by 2030", the World Health Organization calls for the development of new therapeutic interventions. A viewpoint on the learnings from praziquantel research as well as shaping the next generation of drugs is shared.

引用

页码：939 / 942

页数：4

共 20 条

[1] Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model
Abla, Nada
Keiser, Jennifer
Vargas, Mireille
Reimers, Natalie
Haas, Helmut
Spangenberg, Thomas
[J]. PLOS NEGLECTED TROPICAL DISEASES, 2017, 11 (09):
[2] DRUG-RESISTANCE IN SCHISTOSOMES
CIOLI, D
PICAMATTOCCIA, L
ARCHER, S
[J]. PARASITOLOGY TODAY, 1993, 9 (05): : 162 - 166
[3] Human schistosomiasis
Colley, Daniel G.
Bustinduy, Amaya L.
Secor, Evan
King, Charles H.
[J]. LANCET, 2014, 383 (9936) : 2253 - 2264
[4] Identification of annotated bioactive molecules that impair motility of the blood fluke Schistosoma mansoni
Duguet, Thomas B.
Glebov, Anastasia
Hussain, Asimah
Kulkarni, Shashank
Mochalkin, Igor
Geary, Timothy G.
Rashid, Mohammed
Spangenberg, Thomas
Ribeiro, Paula
[J]. INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE, 2020, 13 : 73 - 88
[5] A novel cell-free method to culture Schistosoma mansoni from cercariae to juvenile worm stages for in vitro drug testing
Frahm, Soeren
Anisuzzaman, Anisuzzaman
Prodjinotho, Fabien
Vejzagic, Nermina
Verschoor, Admar
da Costa, Clarissa Prazeres
[J]. PLOS NEGLECTED TROPICAL DISEASES, 2019, 13 (01):
[6] PRAZIQUANTEL - MODE OF ACTION
HARDER, A
ANDREWS, P
THOMAS, H
[J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 1987, 15 (01) : 68 - 70
[7] Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, Jason D.
Blagg, Julian
Price, David A.
Bailey, Simon
DeCrescenzo, Gary A.
Devraj, Rajesh V.
Ellsworth, Edmund
Fobian, Yvette M.
Gibbs, Michael E.
Gilles, Richard W.
Greene, Nigel
Huang, Enoch
Krieger-Burke, Teresa
Loesel, Jens
Wager, Travis
Whiteley, Larry
Zhang, Yao
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (17) : 4872 - 4875
[8] In vitro and in vivo trematode models for chemotherapeutic studies
Keiser, J.
[J]. PARASITOLOGY, 2010, 137 (03) : 589 - 603
[9] A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnostics
Langenberg, Marijke C. C.
Hoogerwerf, Marie-Astrid
Koopman, Jan Pieter R.
Janse, Jacqueline J.
Kos-van Oosterhoud, Janneke
Feijt, Carola
Jochems, Simon P.
de Dood, Claudia J.
van Schuijlenburg, Roos
Ozir-Fazalalikhan, Arifa
Manurung, Mikhael D.
Sartono, Erliyani
van der Beek, Martha T.
Winkel, Beatrice M. F.
Verbeek-Menken, Petra H.
Stam, Koen A.
van Leeuwen, Fijs W. B.
Meij, Pauline
van Diepen, Angela
van Lieshout, Lisette
van Dam, Govert J.
Corstjens, Paul L. A. M.
Hokke, Cornelis H.
Yazdanbakhsh, Maria
Visser, Leo G.
Roestenberg, Meta
[J]. NATURE MEDICINE, 2020, 26 (03) : 326 - +
[10] Life cycle maintenance and drug-sensitivity assays for early drug discovery in Schistosoma mansoni
Lombardo, Flavio C.
Pasche, Valerian
Panic, Gordana
Endriss, Yvette
Keiser, Jennifer
[J]. NATURE PROTOCOLS, 2019, 14 (02) : 461 - 481

← 1 2 →